In Vivo Investigation of Filovirus Glycoprotein-Mediated Infection in a BSL2 Setting.

Paige T Richards, Jos�� Alberto Aguilar Brise��o, Bethany A Brunton, Wendy Maury
Author Information
  1. Paige T Richards: Department of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA.
  2. Jos�� Alberto Aguilar Brise��o: Department of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA.
  3. Bethany A Brunton: Department of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA.
  4. Wendy Maury: Department of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA. wendy-maury@uiowa.edu.

Abstract

Highly pathogenic viruses in the Filoviridae family are causative agents of filovirus disease (FVD). Ebola virus (EBOV) is one such member and, of all filoviruses, represents the largest threat to global public health. The study of FVD has been hampered by the lack of tools to study filovirus infection outside maximum containment laboratories. Recombinant vesicular stomatitis virus (VSV) lacking its native glycoprotein and expressing a filovirus glycoprotein (VSV-filo GP) has improved our understanding of GP-mediated host-cell interactions as well as adaptive and humoral immune responses in in vitro and in vivo studies. Furthermore, mouse models suitable for these studies are readily available. Here, we describe multiple injection routes for investigating filovirus GP-mediated infection and pathogenesis using VSV-filo GP and interferon ��/�� receptor-deficient (Ifnar) mice as models. These tools can be safely used outside maximum containment laboratories, are cost effective, and easy to manipulate.

Keywords

References

  1. MMWR Recomm Rep. 2021 Jan 08;70(1):1-12 [PMID: 33417593]
  2. Hum Vaccin Immunother. 2018;14(9):2107-2113 [PMID: 29757706]
  3. Expert Opin Biol Ther. 2020 Oct;20(10):1187-1201 [PMID: 32602788]
  4. Virulence. 2014 Jan 1;5(1):143-53 [PMID: 24022070]
  5. J Virol. 2014 Nov;88(21):12703-14 [PMID: 25142608]
  6. Nat Rev Dis Primers. 2020 Feb 20;6(1):13 [PMID: 32080199]
  7. Annu Rev Pathol. 2017 Jan 24;12:387-418 [PMID: 27959626]
  8. J Infect Dis. 1998 Sep;178(3):651-61 [PMID: 9728532]
  9. J Infect Dis. 2014 Mar;209(6):960-70 [PMID: 24218508]
  10. Virology. 2008 Aug 1;377(2):255-64 [PMID: 18570964]
  11. Zool Res. 2018 Jan 18;39(1):15-24 [PMID: 29511141]
  12. Pathogens. 2021 Aug 06;10(8): [PMID: 34451457]
  13. Annu Rev Biochem. 1998;67:227-64 [PMID: 9759489]
  14. J Virol. 2006 Mar;80(5):2267-79 [PMID: 16474134]
  15. PLoS Pathog. 2015 Nov 12;11(11):e1005263 [PMID: 26562011]
  16. N Engl J Med. 2020 May 7;382(19):1832-1842 [PMID: 32441897]
  17. Viruses. 2019 Oct 26;11(11): [PMID: 31717793]
  18. Viruses. 2023 Jan 04;15(1): [PMID: 36680198]
  19. J Interferon Cytokine Res. 2009 Sep;29(9):511-20 [PMID: 19694547]
  20. mBio. 2019 May 28;10(3): [PMID: 31138743]
  21. PLoS Negl Trop Dis. 2019 Jun 26;13(6):e0006983 [PMID: 31242184]
  22. Cell Rep. 2020 Mar 24;30(12):4041-4051.e4 [PMID: 32209467]
  23. Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14764-9 [PMID: 9405687]
  24. J Infect Dis. 2011 Nov;204 Suppl 3:S1066-74 [PMID: 21987743]
  25. J Infect Dis. 2023 Nov 13;228(Suppl 7):S571-S581 [PMID: 37348509]
  26. J Virol. 2009 Jul;83(13):6404-15 [PMID: 19369350]
  27. Lancet. 2011 Mar 5;377(9768):849-62 [PMID: 21084112]
  28. EBioMedicine. 2019 Nov;49:223-231 [PMID: 31631035]
  29. Sci Rep. 2023 Mar 13;13(1):4175 [PMID: 36914721]
  30. J Emerg Med. 2004 Jul;27(1):69-73 [PMID: 15219306]
  31. Microorganisms. 2020 Sep 25;8(10): [PMID: 32992829]
  32. PLoS Negl Trop Dis. 2016 Feb 29;10(2):e0004475 [PMID: 26927697]
  33. Methods Enzymol. 2018;602:211-228 [PMID: 29588030]
  34. Virology. 2015 May;479-480:122-30 [PMID: 25843618]
  35. Pathogens. 2021 Aug 27;10(9): [PMID: 34578125]
  36. J Leukoc Biol. 2021 Feb;109(2):309-325 [PMID: 32441445]

Grants

  1. UH2 AI169710/NIAID NIH HHS

MeSH Term

Animals
Mice
Glycoproteins
Filoviridae
Disease Models, Animal
Filoviridae Infections
Receptor, Interferon alpha-beta
Ebolavirus
Mice, Knockout
Vesiculovirus
Humans
Viral Envelope Proteins
Containment of Biohazards

Chemicals

Glycoproteins
Receptor, Interferon alpha-beta
Viral Envelope Proteins

Word Cloud

Created with Highcharts 10.0.0filovirusVSV-filoFVDvirusstudytoolsinfectionoutsidemaximumcontainmentlaboratoriesglycoproteinGPGP-mediatedstudiesmodels��/��receptor-deficientmiceHighlypathogenicvirusesFiloviridaefamilycausativeagentsdiseaseEbolaEBOVonememberfilovirusesrepresentslargestthreatglobalpublichealthhamperedlackRecombinantvesicularstomatitisVSVlackingnativeexpressingimprovedunderstandinghost-cellinteractionswelladaptivehumoralimmuneresponsesvitrovivoFurthermoremousesuitablereadilyavailabledescribemultipleinjectionroutesinvestigatingpathogenesisusinginterferonIfnarcansafelyusedcosteffectiveeasymanipulateVivoInvestigationFilovirusGlycoprotein-MediatedInfectionBSL2SettingIFNIfnar���/���IntranasalINIntraperitonealIPIntravenousIVMousemodelVSV-EBOVVSV-MARV

Similar Articles

Cited By

No available data.